Renal failure associated with tyrosine kinase inhibitors-Case report and review of the literature

Leukemia Research

Volumn 34, Issue 1, 2010, Pages 123-127

  Gafter Gvili, Anat ^a,b   Ram, Ron ^a,b   Gafter, Uzi ^a,b   Shpilberg, Ofer ^a,b   Raanani, Pia ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

CML; Imatinib mesylate; Renal failure; Tyrosine kinase inhibitors

Indexed keywords

BCR ABL PROTEIN; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; KIDNEY FAILURE; KIDNEY TUBULE EXCRETION; MICROALBUMINURIA; NEPHROTOXICITY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUBULAR DYSFUNCTION; TUMOR LYSIS SYNDROME; URINALYSIS;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; KIDNEY FAILURE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 73249130135     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.07.009     Document Type: Article

References (29)

1. Goldman J.M., and Melo J.V. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (2001) 1084-1086
2. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344 (2001) 1038-1042
3. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (2001) 1031-1037
4. Peng B., Lloyd P., and Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44 (2005) 879-894
5. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003) 994-1004
6. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 (2006) 2408-2417
7. Hochhaus A., O'Brien S.G., Guilhot F., Druker B.J., Branford S., Foroni L., et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23 (2009) 1054-1061
8. Vuky J., Isacson C., Fotoohi M., dela Cruz J., Otero H., Picozzi V., et al. Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma. Invest New Drugs 24 (2006) 85-88
9. Vora A., Bhutani M., Sharma A., and Raina V. Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase. Ann Oncol 13 (2002) 1833-1834
10. Dann E.J., Fineman R., and Rowe J.M. Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia. J Clin Oncol 20 (2002) 354-355
11. Kitiyakara C., and Atichartakarn V. Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. Nephrol Dial Transpl 17 (2002) 685-687
12. Ali R., Ozkalemkas F., Ozkan A., Ozcelik T., Ozkocaman V., Akdag I., et al. Tumour lysis syndrome with acute renal failure during imatinib therapy. Leuk Res 31 (2007) 573-574
13. Pou M., Saval N., Vera M., Saurina A., Sole M., Cervantes F., et al. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma 44 (2003) 1239-1241
14. Foringer J.R., Verani R.R., Tjia V.M., Finkel K.W., Samuels J.A., and Guntupalli J.S. Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. Ann Pharmacother 39 (2005) 2136-2138
15. Francois H., Coppo P., Hayman J.P., Fouqueray B., Mougenot B., and Ronco P. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss. Am J Kidney Dis 51 (2008) 298-301
16. Gilbert R.E., Kelly D.J., McKay T., Chadban S., Hill P.A., Cooper M.E., et al. PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 59 (2001) 1324-1332
17. Zoja C., Corna D., Rottoli D., Zanchi C., Abbate M., and Remuzzi G. Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney Int 70 (2006) 97-103
18. Lassila M., Jandeleit-Dahm K., Seah K.K., Smith C.M., Calkin A.C., Allen T.J., et al. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 16 (2005) 363-373
19. Savikko J., Taskinen E., and Von Willebrand E. Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy. Transplantation 75 (2003) 1147-1153
20. Schellings M.W., Baumann M., van Leeuwen R.E., Duisters R.F., Janssen S.H., Schroen B., et al. Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension 47 (2006) 467-474
21. Takikita-Suzuki M., Haneda M., Sasahara M., Owada M.K., Nakagawa T., Isono M., et al. Activation of Src kinase in platelet-derived growth factor-B-dependent tubular regeneration after acute ischemic renal injury. Am J Pathol 163 (2003) 277-286
22. Sonmez M., Ovali E., and Omay S.B. Tumor lysis syndrome during treatment with AMN107 (Nilotinib) in a patient with chronic myelogenous leukemia accelerated phase. J Clin Pharm Ther 33 (2008) 91-92
23. Kantarjian H., Pasquini R., Hamerschlak N., Rousselot P., Holowiecki J., Jootar S., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109 (2007) 5143-5150
24. Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354 (2006) 2531-2541
25. Hochhaus A., Kantarjian H.M., Baccarani M., Lipton J.H., Apperley J.F., Druker B.J., et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109 (2007) 2303-2309
26. Guilhot F., Apperley J., Kim D.W., Bullorsky E.O., Baccarani M., Roboz G.J., et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109 (2007) 4143-4150
27. Holstein S.A., Stokes J.B., and Hohl R.J. Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. Leuk Res 33 (2009) 344-347
28. Yu C.C., Yen T.S., Lowell C.A., and DeFranco A.L. Lupus-like kidney disease in mice deficient in the Src family tyrosine kinases Lyn and Fyn. Curr Biol 11 (2001) 34-38
29. Brave M., Goodman V., Kaminskas E., Farrell A., Timmer W., Pope S., et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 14 (2008) 352-359